Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT56YX
|
|||
| Drug Name |
PBI-4050
|
|||
| Synonyms |
setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Company |
Liminal BioSciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H18O2
|
|||
| Canonical SMILES |
CCCCCC1=CC(=CC=C1)CC(=O)O
|
|||
| InChI |
1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)
|
|||
| InChIKey |
PEGQOIGYZLJMIB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1002101-19-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free fatty acid receptor 1 (GPR40) | Target Info | Agonist | [2] |
| Inflammation-related GPCR EX33 (GPR84) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Insulin secretion | |||
| Reactome | G alpha (q) signalling events | |||
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Incretin Synthesis, Secretion, and Inactivation | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Liminal BioSciences. | |||
| REF 2 | Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.